If you have been reading about GHRH analogue and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone (GHRH) family. Its sequence corresponds to the fully active 44-amino-acid form of human GHRH, with a single structural modification: the addition of a trans-3-hexenoyl group at the N-terminus. That modification is not found in the naturally occurring hormone and was introduced deliberately during development to improve stability against enzymatic degradation. The compound is therefore best described as a stabilized analogue rather than a naturally occurring peptide.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of forty-four amino acids whose sequence reproduces human growth hormone-releasing hormone. Its distinguishing feature sits at the amino terminus, where a trans-3-hexenoyl group replaces the free amine. That acylation slows cleavage by dipeptidyl peptidase IV, an enzyme that otherwise removes the first two residues and inactivates the natural hormone quickly. The modified peptide therefore persists longer in circulation while keeping the same receptor target. It is handled as a lyophilized solid and dissolved shortly before use.
Signaling begins at the GHRH receptor, a class B G protein-coupled receptor displayed on somatotroph cells of the anterior pituitary. Receptor occupancy activates Gs proteins, which raise adenylyl cyclase activity and intracellular cyclic AMP, in turn driving protein kinase A dependent pathways. The downstream output is synthesis and pulsatile secretion of growth hormone into the bloodstream. Hepatic tissue and peripheral sites respond by increasing insulin-like growth factor 1 production. Somatostatin and IGF-1 itself supply negative feedback that caps the size and duration of each secretory burst.
When the particles either pass through each other without interaction or elastically repel during the collision, the gained kinetic energy (related to speed) begins to revert into potential energy, driving the collided particles apart. The decelerating particles will return to the initial distance and beyond into infinity, or stop and repeat the collision (oscillation takes place). This shows that the system, which loses no energy, does not combine (bind) into a solid object, parts of which oscillate at short distances. Therefore, to bind the particles, the kinetic energy gained due to the attraction must be dissipated by resistive force. Complex objects in collision ordinarily undergo inelastic collision, transforming some kinetic energy into internal energy (heat content, which is atomic movement), which is further radiated in the form of photons – the light and heat. Once the energy to escape the gravity is dissipated in the collision, the parts will oscillate at a closer, possibly atomic, distance, thus looking like one solid object. This lost energy, necessary to overcome the potential barrier to separate the objects, is the binding energy. If this binding energy were retained in the system as heat, its mass would not decrease, whereas binding energy lost from the system as heat radiation would itself have mass. It directly represents the "mass deficit" of the cold, bound system. Closely analogous considerations apply in chemical and nuclear reactions.
The grant was intended to support research into the interactions of hydrogen with palladium, nickel or platinum under extreme conditions. In March 2013 Graham K. Hubler, a nuclear physicist who worked for the Naval Research Laboratory for 40 years, was named director. One of the SKINR projects is to replicate a 1991 experiment in which a professor associated with the project, Mark Prelas, says bursts of millions of neutrons a second were recorded, which was stopped because "his research account had been frozen". He claims that the new experiment has already seen "neutron emissions at similar levels to the 1991 observation". In May 2016, the United States House Committee on Armed Services, in its report on the 2017 National Defense Authorization Act, directed the Secretary of Defense to "provide a briefing on the military utility of recent U.S. industrial base LENR advancements to the House Committee on Armed Services by September 22, 2016".
Alginate fiber, which is used in fabric, is usually produced through either microfluidic spinning, wet spinning, or electrospinning to obtain thinner fibers. Those fibers are used to produce alginate nonwoven fabric by carding and needle punching. The resulting felts are used in wound dressings, facial masks, and tissue scaffolds due to its hygroscopic and water retention ability.
Sources: en.wikipedia.org
Stachys affinis in Plants for a Future database This article incorporates text from a publication now in the public domain: Ward, Artemas (1911). "The Grocer's Encyclopedia". The Grocer's Encyclopedia. Crosnes
== Pharmacology == Thiazide and thiazide-like diuretics are among the most efficacious and used drugs for the treatment of hypertension, edema, and major cardiovascular outcomes. Despite more than six decades of clinical use, the mechanism of action by which these drugs cure hypertension after long-term use had remained mysterious. Recently, Garau Gianpiero and co-authors reported that the membrane enzyme NAPE-PLD is a renal and extrarenal target of hydrochlorothiazide, chlortalidone and indapamide, shedding light on their mechanism of action in the treatment of hypertension and cardiovascular diseases. As revealed by the crystal structures of NAPE-PLD in complex with hydrochlorothiazide and pyridoxal phosphate (PLP), thiazide molecules bind within the 9 Angostrom-wide internal channel of NAPE-PLD in a manner competitive with the cofactor PLP. In the presence of bile acids, the association of NAPE-PLD with membranes creates membrane pores as dynamic conductive pathways through which the charged PLP can diffuse through cell membranes and membranes of subcellular compartments (e.g., mitochondria and peroxisome). The fact that thiazide medications promote beneficial effects that involve directly a main protein of the endocannabinoid system, NAPE-PLD, reveals not only a novel target for cardiovascular disease, but a way to modulate efficaciously the endocannabinoid system in therapy. These results can be useful in the management of vascular risk factors,as well as associated leukoencephalopathy and demyelinating disease.
== External links == Amino+Acyl-tRNA+Synthetases at the U.S. National Library of Medicine Medical Subject Headings (MeSH) AARS human gene location in the UCSC Genome Browser. AARS human gene details in the UCSC Genome Browser.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.